Anti-Rheumatic Drugs - Portugal

Portugal

In Portugal, the revenue in the Anti-Rheumatic Drugs market is estimated to reach US$58.22m in 2024.
It is expected to exhibit a compound annual growth rate (CAGR 2024-2029) of 0.99%, leading to a market volume of US$61.17m by 2029.
When compared globally, United States is projected to generate the highest revenue in this market, amounting to US$34,700.00m in 2024.
Portugal's anti-rheumatic drug market is witnessing a surge in demand due to an aging population and increasing prevalence of rheumatic diseases.

Key regions: Germany, United States, India, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Rheumatic Drugs market in Portugal has seen significant growth in recent years.

Customer preferences: Patients in Portugal suffering from rheumatic diseases have shown a preference for biologic drugs over traditional disease-modifying antirheumatic drugs (DMARDs). This trend is in line with global market trends, where biologic drugs are becoming increasingly popular due to their efficacy and specificity in targeting the underlying causes of rheumatic diseases.

Trends in the market: The Anti-Rheumatic Drugs market in Portugal has seen significant growth in recent years, with biologic drugs driving the majority of this growth. This trend is expected to continue in the coming years, with increasing numbers of patients opting for biologic drugs over traditional DMARDs. The market is also seeing the introduction of new biologic drugs, which are expected to further drive growth in the market.

Local special circumstances: Portugal has a high prevalence of rheumatic diseases, with an estimated 20% of the population suffering from some form of rheumatic disease. This high prevalence has led to a significant demand for anti-rheumatic drugs in the country. Additionally, Portugal has a well-established healthcare system that provides access to advanced treatments, including biologic drugs, to patients suffering from rheumatic diseases.

Underlying macroeconomic factors: The growth of the Anti-Rheumatic Drugs market in Portugal is driven by a combination of factors, including the high prevalence of rheumatic diseases in the country, the increasing preference for biologic drugs over traditional DMARDs, and the availability of advanced treatments through the country's healthcare system. Additionally, the overall growth of the pharmaceutical industry in Portugal is contributing to the growth of the Anti-Rheumatic Drugs market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.